Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05304234 · ClinicalTrials.gov registry record · Phase 2
Liver Cancer Disparities in American Indian and Alaska Native Persons
A Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05304234 is a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver that is actively recruiting participants, run by University of Washington. The registered enrollment target is 200 participants, below the 256-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05304234, a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Ultrasound or abbreviated MRI
Study Locations (1)
Oklahoma
- Cherokee Nation Health Service - Tahlequah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05304234
The ClinicalTrials.gov registry entry for NCT05304234 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (22% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ultrasound or abbreviated MRI is the first listed.
NCT05304234 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05304234 about?
NCT05304234 is a clinical study titled "Liver Cancer Disparities in American Indian and Alaska Native Persons". We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
What is the current status of trial NCT05304234?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-04-01. Estimated completion is 2026-09-01.
What conditions does trial NCT05304234 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B.
What interventions are being tested in trial NCT05304234?
The interventions under investigation include: Ultrasound or abbreviated MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05304234?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05304234 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.